Palatin Technologies(US:PTN) Prnewswireยท2025-05-09 11:30Core Insights - Palatin Technologies, Inc. announced promising preclinical data for its melanocortin agonists PL9654 and PL9655, which show potential in treating diabetic retinopathy through inflammation resolution, vascular stabilization, and neuroprotection [1][4] Group 1: Findings on PL9654 and PL9655 - The compounds demonstrated the ability to resolve inflammation, stabilize the blood-retinal barrier, reduce VEGF signaling, and protect retinal ganglion cells, which are critical in preventing vision loss in diabetic retinopathy [2][4] - Efficacy was observed across multiple models and administration routes, including topical delivery [2][4] - The research highlights the unique capability of Palatin's melanocortin data in demonstrating multi-pathway inflammation resolution [4] Group 2: Diabetic Retinopathy Overview - Diabetic retinopathy is a progressive complication of diabetes that damages retinal blood vessels, leading to vision loss and is a leading cause of vision impairment among adults aged 20 to 64 [5] - The prevalence of diabetic retinopathy is projected to increase significantly, with estimates indicating that 11.3 million people in the U.S. will be affected by 2030, rising to 14.6 million by 2050 [8] Group 3: Melanocortin Receptor System - The melanocortin receptor system is crucial for regulating inflammation, immune response, and tissue repair, with agonists showing promise in restoring tissue homeostasis in various diseases [6] - PL9654 and PL9655 are positioned as a new class of anti-inflammatory and neuroprotective therapeutics, with the potential for earlier intervention compared to current therapies [7] Group 4: Company Strategy and Future Outlook - Palatin is focused on developing first-in-class medicines that modulate inflammatory pathways and preserve retinal structure and function [7] - The company aims to form marketing collaborations to maximize the commercial potential of its products [9]